Creating new drugs to enhance cancer immunotherapy for melanoma
Development of selective HDAC6 inhibitors to improve cancer immunotherapy
This study is working on new treatments for melanoma by creating special drugs that target a protein called HDAC6, which helps tumors grow, with the hope of boosting the immune system's ability to fight cancer and improve survival for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Georgetown University NIH-funded |
| Lab location | 1 site (Washington, United States) |
| Project ID | NIH-11017610 on NIH RePORTER |
What this research studies
This research focuses on developing selective inhibitors of HDAC6, a protein that plays a role in cancer progression, to improve immunotherapy outcomes for patients with melanoma. The researchers aim to design and test new HDAC6 inhibitors that can reduce the presence of tumor-associated macrophages, which often promote tumor growth, and enhance the immune response against cancer cells. By using advanced molecular modeling and synthesis techniques, they plan to create approximately 50 new compounds each year for evaluation in laboratory and animal models. The ultimate goal is to find effective treatments that can improve survival rates for patients with advanced melanoma and potentially other cancers.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with advanced melanoma who are seeking new treatment options.
Not a fit: Patients with early-stage melanoma or those who do not have melanoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective immunotherapy options for patients with melanoma, potentially improving survival rates and quality of life.
How similar studies have performed: Previous research has shown promise in using immunotherapy strategies to enhance cancer treatment, indicating that this approach may lead to significant advancements.
Where this research is happening
Washington, United States
- Georgetown University — Washington, United States (Active)
Researchers
- Principal investigator: Villagra, Alejandro V — Georgetown University
- Study coordinator: Villagra, Alejandro V
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.